Avadel pharmaceuticals reports first quarter 2025 financial results and raises guidance

-- generated $52.5 million in net revenue from sales of lumryz™, a 93% increase over the first quarter of 2024 -- -- 2,800 patients on lumryz as of march 31, 2025, a net increase of 300 patients since december 31, 2024 and a 100% year over year increase over the first quarter of 2024 --
AVDL Ratings Summary
AVDL Quant Ranking